Close Menu

NEW YORK – CareDx reported after the close of the market on Thursday that its second quarter revenues rose 76 percent year over year, thanks largely to an 84 percent increase in testing services revenues.

For the three months ended June 30, the molecular diagnostics company reported total revenues of $31.5 million, up from $17.8 million during the same period a year earlier, and beating the average Wall Street estimate of $28.0 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.